Avivagen Announces TSX Venture Exchange Approval For Extension Of Warrants

Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Corporation”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely support immune function, promote general health and performance, announces that it has received approval by the TSX Venture Exchange to extend the expiry date of certain of its outstanding warrants.

The first set of extended warrants are exercisable to purchase 1,163,738 common shares at $1.00 per share. These warrants were issued by Avivagen on December 16, 2014 by way of a private placement and had been set to expire on October 30, 2019. The new expiry date for these warrants is December 16, 2019. The second set of extended warrants are exercisable to purchase 2,774,991 common shares at $0.90 per share. These warrants were issued by Avivagen on June 1, 2016 by way of a private placement and had also been set to expire on October 30, 2019. The new expiry date for these warrants is March 31, 2020.

All other terms and conditions of the warrants remain unchanged. The Company’s intention to seek extension of these warrants was previously announced on October 15, 2019. – Business Wire